Kimberley Brown

529 total citations
29 papers, 324 citations indexed

About

Kimberley Brown is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Kimberley Brown has authored 29 papers receiving a total of 324 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Infectious Diseases, 11 papers in Virology and 7 papers in Emergency Medicine. Recurrent topics in Kimberley Brown's work include HIV/AIDS drug development and treatment (23 papers), HIV/AIDS Research and Interventions (15 papers) and HIV Research and Treatment (11 papers). Kimberley Brown is often cited by papers focused on HIV/AIDS drug development and treatment (23 papers), HIV/AIDS Research and Interventions (15 papers) and HIV Research and Treatment (11 papers). Kimberley Brown collaborates with scholars based in United States, Belgium and Puerto Rico. Kimberley Brown's co-authors include Eric Wong, Erkki Lathouwers, Donghan Luo, Olayemi Osiyemi, Bryan Baugh, Sandra De Meyer, Thomas N. Kakuda, C. Zorrilla, Pieter Verboven and Herta Crauwels and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of Hepatology and JAIDS Journal of Acquired Immune Deficiency Syndromes.

In The Last Decade

Kimberley Brown

26 papers receiving 314 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kimberley Brown United States 10 217 90 88 60 55 29 324
Greer Waldrop United States 10 173 0.8× 39 0.4× 45 0.5× 169 2.8× 27 0.5× 24 366
Wicharn Luesomboon Thailand 11 190 0.9× 124 1.4× 32 0.4× 37 0.6× 104 1.9× 21 286
Annabel Mead Canada 10 113 0.5× 44 0.5× 109 1.2× 196 3.3× 26 0.5× 14 315
Ung Vibol Cambodia 10 219 1.0× 92 1.0× 26 0.3× 83 1.4× 83 1.5× 22 292
Isabelle Rouanet France 8 236 1.1× 87 1.0× 94 1.1× 153 2.5× 192 3.5× 18 479
Sofía Ibarra Spain 11 155 0.7× 59 0.7× 21 0.2× 59 1.0× 113 2.1× 20 309
Wadzanai Samaneka United States 10 111 0.5× 28 0.3× 26 0.3× 66 1.1× 60 1.1× 21 204
Jamie C. Jordan United States 9 243 1.1× 119 1.3× 43 0.5× 68 1.1× 64 1.2× 9 467
Galina Moskaleva United States 7 175 0.8× 42 0.5× 33 0.4× 144 2.4× 105 1.9× 8 323
Jhon Rojas Spain 11 296 1.4× 141 1.6× 11 0.1× 77 1.3× 86 1.6× 19 355

Countries citing papers authored by Kimberley Brown

Since Specialization
Citations

This map shows the geographic impact of Kimberley Brown's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kimberley Brown with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kimberley Brown more than expected).

Fields of papers citing papers by Kimberley Brown

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kimberley Brown. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kimberley Brown. The network helps show where Kimberley Brown may publish in the future.

Co-authorship network of co-authors of Kimberley Brown

This figure shows the co-authorship network connecting the top 25 collaborators of Kimberley Brown. A scholar is included among the top collaborators of Kimberley Brown based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kimberley Brown. Kimberley Brown is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Dunn, Michael, Kenneth Sutton, Denise Sutherland‐Phillips, et al.. (2023). 1550. Engaging Black Women on Cabotegravir LA for PrEP by Optimizing Novel Implementation Strategies (EBONI) Study: Provider Perceptions of Appropriateness of Cabotegravir LA for PrEP for Cis-and-Trans Black Women. Open Forum Infectious Diseases. 10(Supplement_2). 1 indexed citations
3.
Brown, Kimberley, et al.. (2022). Disability, Inclusion and Language-in-Education Policy in the Global South: The Colombian Context. Center for Educational Policy Studies Journal. 12(4). 13–33.
4.
Benson, Carmela, Kirsty Dunn, L. Mesana, et al.. (2020). Antiretroviral Adherence, Drug Resistance, and the Impact of Social Determinants of Health in HIV-1 Patients in the US. AIDS and Behavior. 24(12). 3562–3573. 38 indexed citations
5.
6.
7.
Osiyemi, Olayemi, et al.. (2019). Reduced exposure to darunavir and cobicistat in HIV‐1‐infected pregnant women receiving a darunavir/cobicistat‐based regimen. HIV Medicine. 20(5). 337–343. 19 indexed citations
8.
Huhn, Gregory, Joseph J. Eron, Pierre‐Marie Girard, et al.. (2019). Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study. AIDS Research and Therapy. 16(1). 23–23. 6 indexed citations
9.
Brown, Kimberley, et al.. (2018). Prevalence of Darunavir Resistance in the United States from 2010 to 2017. AIDS Research and Human Retroviruses. 34(12). 1036–1043. 9 indexed citations
10.
Opsomer, Magda, Dessislava I. Dimitrova, Simon Vanveggel, et al.. (2018). Evaluation of Cardiovascular Disease Risk in HIV-1–Infected Patients Treated with Darunavir. Drugs in R&D. 18(3). 199–210. 9 indexed citations
11.
Osiyemi, Olayemi, et al.. (2018). Pharmacokinetics, Antiviral Activity, and Safety of Rilpivirine in Pregnant Women with HIV-1 Infection: Results of a Phase 3b, Multicenter, Open-Label Study. Infectious Diseases and Therapy. 7(1). 147–159. 18 indexed citations
12.
Spinner, Christoph D., Bruce Rashbaum, Cheryl McDonald, et al.. (2018). 541. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment Naïve Patients: Week 48 Results in Subgroups Based on Baseline Viral Load, CD4+ Count, and WHO Clinical Staging. Open Forum Infectious Diseases. 5(suppl_1). S201–S201. 1 indexed citations
13.
Brown, Kimberley, et al.. (2017). Treating Older HIV-1-infected Subjects With Cobicistat-boosted Darunavir in a 48-week Phase 3 Trial. Reviews on Recent Clinical Trials. 12(3). 174–181. 1 indexed citations
14.
Kakuda, Thomas N., Barbara M. Ryan, C. Zorrilla, et al.. (2016). Pharmacokinetics of once‐daily darunavir/ritonavir in HIV‐1–infected pregnant women. HIV Medicine. 17(9). 643–652. 18 indexed citations
15.
Ramgopal, Moti, Olayemi Osiyemi, Carmen Zorrilla, et al.. (2016). Pharmacokinetics of Total and Unbound Etravirine in HIV-1–Infected Pregnant Women. JAIDS Journal of Acquired Immune Deficiency Syndromes. 73(3). 268–274. 11 indexed citations
16.
Wright, Rodney, Bryan Baugh, Kimberley Brown, et al.. (2013). Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV‐1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily. HIV Medicine. 15(1). 50–56. 41 indexed citations
17.
Zorrilla, C., Rodney Wright, Olayemi Osiyemi, et al.. (2012). Total and unbound darunavir (DRV) pharmacokinetics (PK) in HIV‐1‐infected pregnant women. Journal of the International AIDS Society. 15(S4). 1–2. 3 indexed citations
18.
Brown, Kimberley. (2003). A review to examine the use of SF-36 in cardiac rehabilitation. British Journal of Nursing. 12(15). 904–909. 15 indexed citations
19.
Brown, Kimberley, et al.. (1995). Panic! Unix system crash dump analysis. CERN Document Server (European Organization for Nuclear Research). 2 indexed citations
20.
Bigos, Stanley J., Kimberley Brown, Richard A. Deyo, et al.. (1995). Acute low back problems in adults: Assessment and treatment. 51(2). 469–484. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Greer Waldrop Breakdown of academic impact, for papers by Wicharn Luesomboon Breakdown of academic impact, for papers by Annabel Mead Breakdown of academic impact, for papers by Ung Vibol Breakdown of academic impact, for papers by Isabelle Rouanet Breakdown of academic impact, for papers by Sofía Ibarra Breakdown of academic impact, for papers by Wadzanai Samaneka Breakdown of academic impact, for papers by Jamie C. Jordan Breakdown of academic impact, for papers by Galina Moskaleva Breakdown of academic impact, for papers by Jhon Rojas
Rankless by CCL
2026